Odimma Therapeutics
Created in 2017
Up & running (A)
Existing signals show a regular activitySocial networks
1,118Activities
Technologies
Entity types
Location
1 Rue Jean-Dominique Cassini, 67400 Illkirch-Graffenstaden, France
Illkirch-Graffenstaden
France
Employees
Scale: 2-10
Estimated: 6
Engaged catalyst
12
0 0Added in Motherbase
2 years, 2 months ago
Value proposition
Empowering Personalized Immunotherapy to Treat Cancer
Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy.
Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.
Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.
By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.
Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic
Onco-Immunology, Cancer Immunotherapy, Research & Development, DeepTech, and Personalized MedicineOriginal language
Empowering Personalized Immunotherapy to Treat Cancer
Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy.
Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.
Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.
By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.
Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic
Odimma therapeutics
Empowering personalized immunotherapy to treat cancer
https://www.odimma-therapeutics.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Quest for health Startup accelerator & VC | Quest for health Startup accelerator & VC | Other 15 May 2025 | | |
 Quest for change Startup accelerator & VC | Quest for change Startup accelerator & VC | Other 20 Sep 2023 | | |
 Ville et Eurométropole de Strasbourg National and local authorities, Government Administration, French metropolis | Ville et Eurométropole de Strasbourg National and local authorities, Government Administration, French metropolis | Other 20 Sep 2023 | | |
 Région Grand Est National and local authorities, Government Administration | Région Grand Est National and local authorities, Government Administration | Other 8 Dec 2023 | | |
 Eurasanté Startup accelerator & VC, Biotechnology, Biotechnology Research | Eurasanté Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 30 Nov 2022 | | |
 Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 30 Nov 2022 | | |
 Clubster NSL Public business cluster, French Cluster, Civic and Social Organizations | Clubster NSL Public business cluster, French Cluster, Civic and Social Organizations | Other 30 Nov 2022 | | |
 Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Other 30 Nov 2022 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 8 Dec 2023 | | |
 SEMIA Startup accelerator & VC, Business Consulting and Services | SEMIA Startup accelerator & VC, Business Consulting and Services | Other 4 May 2023 | | |